# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Oppenheimer analyst Leland Gershell initiates coverage on Immunovant (NASDAQ:IMVT) with a Outperform rating and announces Pr...
Truist Securities analyst Robyn Karnauskas reiterates Immunovant (NASDAQ:IMVT) with a Buy and maintains $48 price target.
Goldman Sachs analyst Corinne Johnson initiates coverage on Immunovant (NASDAQ:IMVT) with a Buy rating and announces Price T...
Wolfe Research analyst Andy Chen initiates coverage on Immunovant (NASDAQ:IMVT) with a Outperform rating and announces Price...
Immunovant (NASDAQ:IMVT) reported quarterly losses of $(0.36) per share. This is a 26.53 percent increase over losses of $(0.49...